SURVANTA Drug Profile

Summary for Tradename: SURVANTA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for SURVANTA
Recent Clinical Trials:	See clinical trials for SURVANTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SURVANTA

See drug prices for SURVANTA

Recent Clinical Trials for SURVANTA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Lokmanya Tilak Municipal General Hospital	Phase 2/Phase 3
Chacha Nehru Bal Chikitsalya, Delhi	Phase 2/Phase 3
St. John's Medical College, Bangalore	Phase 2/Phase 3

See all SURVANTA clinical trials

Recent Litigation for SURVANTA

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD.	2023-01-19
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN INC.	2021-07-28

See all SURVANTA litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SURVANTA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SURVANTA Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for SURVANTA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	7,951,781	2026-11-02	Patent claims search
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	8,236,750	2025-07-27	Patent claims search
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	8,263,125	2022-08-05	Patent claims search
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	8,268,352	2022-08-05	Patent claims search
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	8,404,230	2029-09-08	Patent claims search

SURVANTA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Biologic Drugs: A Focus on SURVANTA

Introduction

The biologics market is experiencing rapid growth, driven by increasing demand for targeted and effective treatments for a range of diseases. This article will delve into the market dynamics and financial trajectory of biologic drugs, with a specific focus on SURVANTA, a lung surfactant used to treat Respiratory Distress Syndrome (RDS) in premature infants.

Global Biologics Market Overview

The global biologics market is projected to grow significantly over the next decade. In 2022, the market was valued at USD 461.74 billion and is expected to grow at a CAGR of 10.3% from 2023 to 2030[1]. By 2033, the market is anticipated to reach around USD 1,374.51 billion, growing at a CAGR of 10.4% during the forecast period 2024 to 2033[4].

Key Drivers of the Biologics Market

Several factors are driving the growth of the biologics market:

• Increasing Burden of Chronic Diseases: The rising prevalence of cancer, neurological diseases, genetic diseases, and autoimmune diseases is a significant driver[1][4].
• Approval of Novel Biologic Drugs: The approval of new biologic therapies such as gene therapy, RNAi therapeutics, and antibody-drug conjugates is propelling market growth[1][4].
• Personalized Medicine and Companion Diagnostics: Advancements in personalized medicine and companion diagnostics are making treatments more targeted and effective, increasing demand for biologic products[1].

Regional Market Dynamics

North America

North America holds the largest revenue share in the biologics market, accounting for 44.37% in 2022 and 46% in 2023. This dominance is due to the high prevalence of chronic diseases, the presence of leading biopharmaceutical companies, favorable reimbursement policies, and significant investments in R&D[1][4].

Asia Pacific

The Asia Pacific region is expected to expand at a CAGR of 11.2% during the forecast period, driven by growing healthcare needs and increasing investments in biotechnology[4].

SURVANTA: A Specific Biologic Drug

Clinical Use and Efficacy

SURVANTA (beractant) is a lung surfactant used to treat Respiratory Distress Syndrome (RDS) in premature infants. It replenishes surfactant and restores surface activity to the lungs, significantly reducing the incidence of RDS, mortality due to RDS, and air leak complications[2].

Clinical Studies

Clinical trials have demonstrated the efficacy of SURVANTA. In multiple-dose studies, SURVANTA significantly reduced the incidence of RDS and related mortality compared to control groups. Follow-up evaluations have shown no long-term complications or sequelae of SURVANTA therapy[2].

Market Impact

SURVANTA, as a part of the broader lung surfactant market, benefits from the overall growth trends in biologics. The increasing prevalence of premature births and the critical need for effective treatments for RDS contribute to the demand for SURVANTA.

Financial Trajectory

Revenue Growth

The biologics market, including products like SURVANTA, is expected to see substantial revenue growth. The global biologics market is projected to reach USD 1,374.51 billion by 2033, up from USD 511.04 billion in 2024[4].

Segment Performance

• Oncology Segment: Dominates the biologics industry with a share of 29.40% in 2023, but other segments like hematological disorders are expected to grow at a faster CAGR[4].
• Monoclonal Antibodies: Account for a significant share of the market, but segments like antisense and RNAi therapeutics are anticipated to expand at a higher CAGR of 20.7% during the forecast period[4].

Manufacturing and Outsourcing

The in-house manufacturing segment dominates the market with an 85.87% share in 2023, but the outsourcing segment is projected to expand at a CAGR of 10.8% during the forecast period[4].

Competitive Landscape

SURVANTA competes in a market with other lung surfactants, such as Surfaxin and Exosurf. Studies have shown that SURVANTA is effective and comparable to other surfactant products, with some studies indicating superiority of certain products over others in specific endpoints[3].

Regulatory and Approval Environment

The approval and regulatory environment play a crucial role in the market dynamics of biologic drugs. The FDA's stringent review process ensures that products like SURVANTA meet high standards of efficacy and safety before they are released to the market[3].

Conclusion

The biologics market, including products like SURVANTA, is poised for significant growth driven by increasing demand for targeted therapies and advancements in biotechnology. SURVANTA's efficacy in treating RDS in premature infants positions it as a valuable asset in the broader biologics market.

Key Takeaways

• The global biologics market is expected to grow at a CAGR of 10.3% to 10.4% from 2023 to 2033.
• SURVANTA is a critical biologic drug for treating RDS in premature infants.
• North America dominates the biologics market due to high disease prevalence and favorable R&D and reimbursement environments.
• The Asia Pacific region is expected to grow at a higher CAGR during the forecast period.
• The market is driven by the approval of novel biologic drugs and advancements in personalized medicine.

FAQs

Q: What is the current size and projected growth of the global biologics market?

The global biologics market was valued at USD 461.74 billion in 2022 and is expected to grow at a CAGR of 10.3% from 2023 to 2030, reaching around USD 1,374.51 billion by 2033[1][4].

Q: What are the key drivers of the biologics market?

Key drivers include the increasing burden of chronic diseases, approval of novel biologic drugs, and advancements in personalized medicine and companion diagnostics[1][4].

Q: What is SURVANTA used for?

SURVANTA is used to treat Respiratory Distress Syndrome (RDS) in premature infants by replenishing surfactant and restoring surface activity to the lungs[2].

Q: How does SURVANTA compare to other lung surfactants?

SURVANTA has been shown to be effective and comparable to other surfactant products, with some studies indicating superiority in specific endpoints[3].

Q: What is the regional market dynamics for the biologics market?

North America holds the largest revenue share, while the Asia Pacific region is expected to grow at a higher CAGR during the forecast period[1][4].